Matrix Labs Of India Considers Sale Of Docpharma Belgian Unit
This article was originally published in PharmAsia News
Executive Summary
India's Matrix Labs is considering a sale of its Docpharma unit in Belgium three years after acquiring the firm in one of the largest international drug maker deals at the time. A controlling interest in Matrix itself is held by U.S.-based Mylan Labs. Matrix determined Docpharma was not a strategic fit for its generics business. Matrix's chairman said the firm also is exploring other "strategic alternatives" for Docpharma. (Click here for more